Skip to main content
IDWeek 2021 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
View Session ViewAttendees 52
Interactive Session

04 - Case-based Guidelines Session

Thursday, September 30, 2021
11:00 AM - 12:15 PM EDT

    Moderator(s)

  • Ravi Jhaveri, MD

    Professor of Pediatrics
    Northwestern University Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, IL, United States

    Dynavax (Individual(s) Involved: Self): Consultant; Elsevier (Individual(s) Involved: Self): Editorial Stipend as Co-editor in Chief, Clinical Therapeutics, Other Financial or Material Support; Medimmune/AstraZeneca (Individual(s) Involved: Self): Consultant; Saol Therapeutics (Individual(s) Involved: Self): Consultant; Seqirus (Individual(s) Involved: Self): Consultant

    • Speaker(s)

  • Pranita Tamma, MD, MHS

    Associate Professor
    Johns Hopkins
    Baltimore, MD, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

  • John Lynch, MD

    Associate Professor
    University of Washington
    Seattle, WA, United States

    Alaska Airlines (Individual(s) Involved: Self): Consultant; National Football League (Individual(s) Involved: Self): Consultant; Vertical World (Individual(s) Involved: Self): Consultant; Washington State Hospital Association (Individual(s) Involved: Self): Consultant

  • Angela Caliendo, MD, PhD

    Professor
    Brown University
    Providence, RI, United States

    Chromacode (Individual(s) Involved: Self): Consultant; Danaher/Cepheid (Individual(s) Involved: Self): Consultant; First Light (Individual(s) Involved: Self): Consultant; Hologic (Individual(s) Involved: Self): Grant/Research Support; IDSA (Individual(s) Involved: Self): Board Member; Quidel (Individual(s) Involved: Self): Consultant; Roche Diagnostics (Individual(s) Involved: Self): Consultant; Roche Molecular (Individual(s) Involved: Self): Consultant; Visby (Individual(s) Involved: Self): Consultant

  • Adarsh Bhimraj, MD

    Director, Infectious Diseases Fellowship and Education
    Division of Infectious Diseases, Houston Methodist Hospital
    Center of Excellence for Infectious Diseases Houston Methodist Research Institute
    Cleveland, Ohio, United States

    I do not have any relevant financial / non-financial relationships with any proprietary interests.

Participants should be aware of the following financial/non-financial relationships:
Ravi Jhaveri, MD: Dynavax (Individual(s) Involved: Self): Consultant; Elsevier (Individual(s) Involved: Self): Editorial Stipend as Co-editor in Chief, Clinical Therapeutics, Other Financial or Material Support; Medimmune/AstraZeneca (Individual(s) Involved: Self): Consultant; Saol Therapeutics (Individual(s) Involved: Self): Consultant; Seqirus (Individual(s) Involved: Self): Consultant
Pranita Tamma, MD, MHS: I do not have any relevant financial / non-financial relationships with any proprietary interests.
John B. Lynch, MD: Alaska Airlines (Individual(s) Involved: Self): Consultant; National Football League (Individual(s) Involved: Self): Consultant; Vertical World (Individual(s) Involved: Self): Consultant; Washington State Hospital Association (Individual(s) Involved: Self): Consultant
Angela Caliendo, MD, PhD: Chromacode (Individual(s) Involved: Self): Consultant; Danaher/Cepheid (Individual(s) Involved: Self): Consultant; First Light (Individual(s) Involved: Self): Consultant; Hologic (Individual(s) Involved: Self): Grant/Research Support; IDSA (Individual(s) Involved: Self): Board Member; Quidel (Individual(s) Involved: Self): Consultant; Roche Diagnostics (Individual(s) Involved: Self): Consultant; Roche Molecular (Individual(s) Involved: Self): Consultant; Visby (Individual(s) Involved: Self): Consultant
Adarsh Bhimraj, MD: I do not have any relevant financial / non-financial relationships with any proprietary interests.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit

No CPE credits

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • compare the safety and efficacy of different pharmacologic therapies for treatment of COVID-19 infection amidst rapidly emerging literature
  • discuss how to make decisions about infection prevention when caring for patients with suspected or known COVID-19
  • select appropriate methods for diagnosing SARS-CoV-2 infection
  • select antibiotic therapy for infections caused by extended-spectrum beta-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, and Pseudomonas aeruginosa with difficult-to-treat resistance

Presentations:

  • Antimicrobial Resistant Gram-Negative Infections: A Case Based Approach

    Speaker: Pranita Tamma, MD, MHS – Johns Hopkins

  • Infection Prevention for COVID-19: A Case Based Approach

    Speaker: John B. Lynch, MD – University of Washington

  • Molecular Diagnostics and Antigen Testing for COVID-19: A Case Based Approach

    Speaker: Angela Caliendo, MD, PhD – Brown University

  • Treatment and Management of COVID-19: A Case Based Approach

    Speaker: Adarsh Bhimraj, MD – Cleveland Clinic Foundation